A Post-Marketing Safety Study of Dorzagliatin in Patients With Type 2 Diabetes

This study adopts a multicenter, prospective, and observational cohort study design and does not involve randomization, control, and blinding. Patients with type 2 diabetes mellitus who were prescribed Dorzagliatin according to the package insert and physician's judgment in routine medical practice setting will be included, and the data of these patients during 52-week Dorzagliatin treatment will be collected to evaluate the safety of long-term medication.

Inclusion criteria

-

Patients must meet all of the following inclusion criteria to be eligible for this study:

• Male or female ≥ 18 years of age at the time of signing the informed consent form;
• Patients with type 2 diabetes mellitus diagnosed at screening;
• Patients who have been prescribed Dorzagliatin according to the package insert and physician's judgment (the prescription should be made before enrolling the patient in this study and is independent of the enrollment decision);
• Willingness to participate in the study and sign written informed consent.

Exclusion criteria

-

Patients will not be eligible if they meet any of the following criteria:

• Other types of clinically diagnosed diabetes, such as type 1 diabetes or other special types of diabetes;
• Patients who, in the opinion of the investigator, are at risk of allergy or intolerance to any component of Dorzagliatin;
• Patients who, in the judgment of the investigator, cannot complete or are not suitable for this study.